JMS Co.,Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018
February 07, 2018
Share
JMS Co.,Ltd. announced consolidated earnings results for the nine months ended December 31, 2017. For the period, the consolidated company reported net sales of ¥41,983 million, operating profit of ¥548 million, ordinary profit of ¥713 million, profit attributable to owners of the parent of the company of ¥497 million or net income per share of ¥20.43 compared to net sales of ¥41,773 million, operating profit of ¥1,053 million, ordinary profit of ¥1,397 million, profit attributable to owners of the parent of the company of ¥1,174 million or net income per share of ¥48.18 for the same period last year. Profit before income taxes was ¥710 million against ¥1,404 million a year ago.
For the full year of fiscal year ending March 31, 2018, the consolidated company expects net sales of ¥56,000 million, operating income of ¥700 million, ordinary income of ¥900 million, profit attributable to owners of the parent of the company of ¥600 million or basic earnings per share of ¥24.62.
JMS CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and drugs. The Company operates through five geographical segments including Japan, Singapore, China, Philippines and Germany. The Company is engaged in the manufacture and sale of infusion and nutrition products, dialysis products, surgery products, blood and cell products and other products. The Companyâs main products include infusion & transfusion set, syringe pump, surgical gown, dialysis kit, peritoneal dialysate, microcatheter, blood bag, among others. The Company is also involved in the provision of maintenance service and other related services.
JMS Co.,Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018